Discourage Using the New Oral Antiplatelet Drug Zontivity Alone

September 2014

You'll hear controversy about the new oral antiplatelet drug, Zontivity (zon-TIV-i-tee, vorapaxar).

It's the first protease-activated receptor-1 (PAR-1) antagonist...and inhibits platelet aggregation for about 4 weeks.

It's approved for use with low-dose aspirin and/or clopidogrel after a heart attack or in patients with peripheral artery disease...to further reduce CV events or death.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Cardiology Suggest Saving Niacin for Special Situations
Vaccines Suggest Intranasal FluMist for Young, Healthy Children
Depression Use Low Antipsychotic Doses When Adding to an Antidepressant
Smoking Cessation Save Combos with Chantix for When Other Options Don't Work
Infectious Diseases Warn About the High Cost of Some Cold Sore Treatments
Statins Point Out Statins' CV Benefits STILL Outweigh Diabetes Risk
Oral Health Explain Electric Toothbrushes Can Reduce Plaque More Than Manual Brushes
Diuretics Don't Rely on Potassium from Foods to Treat Hypokalemia
Antithrombotics Discourage Using the New Oral Antiplatelet Drug Zontivity Alone
E-Prescriptions Suggest Sending E-Rxs At the End of Each Patient Visit
ADHD Don't Recommend an ECG Before Beginning Stimulants in Most Kids
Med Administration Recommend Diluting Liquid Meds Before Enteral Tube Administration
Opioids DEA's switch of all hydrocodone COMBOS (Vicodin, Tussionex, etc) to Schedule II on October 6th will cause lots of confusion

Discourage Using the New Oral Antiplatelet Drug Zontivity Alone

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents